Blake Insomnia Therapeutics, Inc. is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. Our patent-pending compound, Zleepax™ (ZLX-1), has demonstrated efficacy without causing side effects identified as the No. 1 problem with current sleep medication. Blake Insomnia completed its reverse merger into NASDAQ OTC in second half of 2015.
The Blake Insomnia management team consist of founder and CEO Birger Jan Olsen. The company is currently transitioning from a lean startup organization into a more mature organizational form. Plans for 2016 include establishing a board of directors, appointing a science advisory board and hiring additional required staff.
In 2007, we filed patent application EP20080758258, covering the use of specific beta blockers, alone or in combination with other anti-insomnia drugs, for the treatment of stress-related insomnia.